Voyager Therapeutics, Inc. (28)
Browse by Contract Category
Contracts
-
Option and License Agreement by and between the Registrant and Novartis Pharma AG, dated March 4, 2022
(Filed With SEC on May 4, 2022)
-
Employment Agreement, by and between Voyager Therapeutics, Inc. and Alfred Sandrock, M.D., Ph.D., effective as of March 22, 2022
(Filed With SEC on March 22, 2022)
-
Sublease Agreement, by and between Registrant and BioNTech US Inc., dated September 3, 2021
(Filed With SEC on November 2, 2021)
-
Description of Registrants Securities
(Filed With SEC on March 3, 2020)
-
Amendment No. 1 to the Collaboration and License Agreement, by and between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc., dated June 14, 2019
(Filed With SEC on August 9, 2019)
-
Form of Non-Qualified Stock Option Agreement for Inducement Grant
(Filed With SEC on February 26, 2019)
-
Employment Agreement, by and between the Registrant and Julie Burek, dated as of October 1, 2021
(Filed With SEC on March 8, 2022)
-
Consulting Agreement by and between the Registrant and Allison Dorval, dated as of November 26, 2021
(Filed With SEC on March 8, 2022)
-
Separation and Release of Claims Agreement by and between the Registrant and Allison Dorval, effective December 13, 2021
(Filed With SEC on March 8, 2022)
-
Amended and Restated Employment Agreement, by and between Voyager Therapeutics, Inc. and Robin Swartz, effective as of February 7, 2022
(Filed With SEC on February 3, 2022)
-
Consulting Agreement by and between Voyager Therapeutics, Inc. and Alfred Sandrock, effective as of February 7, 2022
(Filed With SEC on February 3, 2022)
-
Option and License Agreement, by and between the Registrant and Pfizer Inc., dated October 1, 2021
(Filed With SEC on November 2, 2021)
-
Amendment No. 1 to Employment Agreement, by and between the Registrant and Glenn Pierce, dated June 7, 2021
(Filed With SEC on June 8, 2021)
-
Transition, Separation and Release of Claims Agreement, by and between the Registrant and G. Andre Turenne, dated May 19, 2021
(Filed With SEC on May 19, 2021)
-
Employment Agreement, by and between the Registrant and Glenn Pierce, M.D., Ph.D., dated May 19, 2021
(Filed With SEC on May 19, 2021)
-
Employment Agreement, by and between the Registrant and Michael Higgins, dated May 19, 2021
(Filed With SEC on May 19, 2021)
-
AMENDMENT NO. 2 TO CONSULTING AGREEMENT
(Filed With SEC on February 25, 2021)
-
First Amendment to Amended and Restated Option and License Agreement with Genzyme Corporation, dated September 20, 2020
(Filed With SEC on November 9, 2020)
-
Lease Agreement, by and between the Registrant and HCP/King 75 Hayden LLC, dated March 16, 2020
(Filed With SEC on March 19, 2020)
-
Transition, Separation, and Release of Claims Agreement, by and between the Company and Matthew P. Ottmer, dated as of February 12, 2020
(Filed With SEC on February 14, 2020)
-
Amendment No. 1 to Consulting Agreement, by and between the Corporation and Dinah Sah, dated September 16, 2019
(Filed With SEC on November 6, 2019)
-
Amendment No. 1 to Consulting Agreement, by and between the Corporation and Steven M. Paul, M.D., dated July 9, 2019
(Filed With SEC on November 6, 2019)
-
Consulting Agreement, by and between Voyager Therapeutics, Inc. and Dinah Sah, Ph.D., dated June 28, 2019
(Filed With SEC on August 9, 2019)
-
Amended and Restated Option and License Agreement, by and between Voyager Therapeutics, Inc. and Genzyme Corporation, dated June 14, 2019
(Filed With SEC on August 9, 2019)
-
Termination Agreement, by and between Voyager Therapeutics, Inc. and Genzyme Corporation, dated June 14, 2019
(Filed With SEC on August 9, 2019)
-
Employment Agreement, by and between Voyager Therapeutics, Inc. and Omar Khwaja, M.D., Ph.D, dated May 20, 2019
(Filed With SEC on August 9, 2019)
-
Retirement Agreement, by and between the Company and Dinah Sah, dated as of May 20, 2019
(Filed With SEC on May 21, 2019)
-
Employment Agreement, by and between the Registrant and Robert W. Hesslein, dated January 15, 2019
(Filed With SEC on May 7, 2019)